Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNACNASDAQ:LENZNASDAQ:REPLNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNACSocial Capital Suvretta Holdings Corp. III$9.28-7.2%$9.56$8.03▼$10.55$237.94MN/A178,857 shs8,160 shsLENZLENZ Therapeutics$29.16-0.1%$25.72$14.42▼$38.93$820.74M0.41183,970 shs172,416 shsREPLReplimune Group$9.57+6.6%$8.39$4.93▼$17.00$737.72M0.68944,323 shs2.32 million shsVIRVir Biotechnology$5.07+2.6%$5.50$4.32▼$14.45$700.87M1.361.40 million shs1.72 million shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNACSocial Capital Suvretta Holdings Corp. III0.00%0.00%0.00%0.00%0.00%LENZLENZ Therapeutics0.00%+3.98%-0.78%+35.98%+91.56%REPLReplimune Group0.00%+6.95%-10.79%-26.32%+69.45%VIRVir Biotechnology0.00%+8.00%-21.10%-38.64%-52.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNACSocial Capital Suvretta Holdings Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/ALENZLENZ Therapeutics1.9294 of 5 stars3.60.00.00.03.52.50.0REPLReplimune Group4.2242 of 5 stars3.61.00.04.54.02.50.6VIRVir Biotechnology2.9947 of 5 stars3.41.00.00.03.33.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNACSocial Capital Suvretta Holdings Corp. III 0.00N/AN/AN/ALENZLENZ Therapeutics 3.17Buy$46.6059.81% UpsideREPLReplimune Group 3.11Buy$19.75106.37% UpsideVIRVir Biotechnology 2.86Moderate Buy$32.86548.07% UpsideCurrent Analyst Ratings BreakdownLatest DNAC, LENZ, REPL, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.003/20/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.003/18/2025LENZLENZ TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNACSocial Capital Suvretta Holdings Corp. IIIN/AN/AN/AN/A($0.33) per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/AVIRVir Biotechnology$14.30M49.00N/AN/A$11.82 per share0.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNACSocial Capital Suvretta Holdings Corp. III-$2.33MN/A0.00∞N/AN/AN/AN/AN/ALENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%8/13/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)VIRVir Biotechnology-$615.06M-$4.22N/AN/AN/A-678.40%-36.71%-31.00%7/30/2025 (Estimated)Latest DNAC, LENZ, REPL, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNACSocial Capital Suvretta Holdings Corp. IIIN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNACSocial Capital Suvretta Holdings Corp. IIIN/A0.110.11LENZLENZ TherapeuticsN/A28.6328.63REPLReplimune Group0.1411.4311.43VIRVir BiotechnologyN/A8.948.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNACSocial Capital Suvretta Holdings Corp. III94.13%LENZLENZ Therapeutics54.32%REPLReplimune Group92.53%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipDNACSocial Capital Suvretta Holdings Corp. IIIN/ALENZLENZ Therapeutics38.40%REPLReplimune Group8.80%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNACSocial Capital Suvretta Holdings Corp. III425.64 millionN/ANot OptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/AREPLReplimune Group21077.09 million70.24 millionOptionableVIRVir Biotechnology580138.24 million116.24 millionOptionableDNAC, LENZ, REPL, and VIR HeadlinesRecent News About These CompaniesVir Biotechnology (NASDAQ:VIR) Stock Price Down 7.6% - Here's What HappenedMay 31 at 12:48 PM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading 6.6% Higher - What's Next?May 30 at 2:08 PM | marketbeat.comVir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and OncologyMay 29, 2025 | investing.comVir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025May 28, 2025 | businesswire.comVoloridge Investment Management LLC Lowers Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)May 28, 2025 | marketbeat.comWoodline Partners LP Makes New $991,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)May 28, 2025 | marketbeat.comMillennium Management LLC Has $12.59 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)May 26, 2025 | marketbeat.comVir Biotechnology's (VIR) Buy Rating Reaffirmed at Needham & Company LLCMay 24, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of VIR Q2 EarningsMay 24, 2025 | marketbeat.comBrokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Target Price at $32.86May 23, 2025 | americanbankingnews.comGilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programsMay 22, 2025 | fiercebiotech.comVir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)May 22, 2025 | benzinga.comPoint72 Asset Management L.P. Raises Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)May 22, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by D. E. Shaw & Co. Inc.May 21, 2025 | marketbeat.comStonepine Capital Management LLC Takes Position in Vir Biotechnology, Inc. (NASDAQ:VIR)May 20, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 20, 2025 | marketbeat.comSphera Funds Management LTD. Boosts Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)May 18, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Algert Global LLCMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Reduces Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)May 15, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Hudson Bay Capital Management LPMay 15, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at Needham & Company LLCMay 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNAC, LENZ, REPL, and VIR Company DescriptionsSocial Capital Suvretta Holdings Corp. III NASDAQ:DNACSocial Capital Suvretta Holdings Corp. III does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. Social Capital Suvretta Holdings Corp. III was incorporated in 2021 and is based in Henderson, Nevada.LENZ Therapeutics NASDAQ:LENZ$29.16 -0.04 (-0.14%) Closing price 04:00 PM EasternExtended Trading$29.18 +0.02 (+0.07%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Replimune Group NASDAQ:REPL$9.57 +0.59 (+6.57%) Closing price 04:00 PM EasternExtended Trading$9.63 +0.06 (+0.64%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Vir Biotechnology NASDAQ:VIR$5.07 +0.13 (+2.63%) Closing price 04:00 PM EasternExtended Trading$5.08 +0.00 (+0.10%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
